International Classification of Diseases, Tenth Revision defines opioid dependence syndrome as a cluster of behavioural, cognitive and physiological phenomena that develop after repeated opioid use (WHO, World Health Organization, 1993). In 2018, there were 57.8 million people globally who were past year users of opioids. Ireland has a prevalence of around 6.18 per 1000 population accounting for 18,988 high-risk opioid users (EMCDDA, 2019).

In Europe, opioid use (predominantly heroin) is the main reason for people entering specialised drug treatment and represents 34% of all treatment requests (EMCDDA, 2020). As of March 2021, there were 11,445 people registered with the Central Treatment List in Ireland receiving opioid agonist treatment (OAT).

Integrated drug treatment programs combine pharmacotherapy with a range of medical and psychosocial interventions (HSE, 2016). OATs (primarily methadone and buprenorphine) are the gold standard pharmacotherapy in the treatment of opioid use disorders (Volkow et al., Reference Volkow, Jones, Einstein and Wargo2019).

OAT is known to keep people in treatment, reduce illicit opioid use, reduce related risk behaviour and mortality and improve mental health. This impact may be enhanced with psychosocial support together (EMCDDA, 2017).

Oral methadone was introduced as the standard pharmacological treatment for the management of opioid dependence in Ireland in 1971, and it has remained the mainstay of treatment since (Delargy et al., Reference Delargy, Crowley and Van Hout2019). The introduction of sublingual buprenorphine in 2005 has offered a greater choice of treatment for problem opioid users in Ireland (Long, Reference Long2006).

Methadone is a full agonist of the mu opioid receptor, while buprenorphine is a partial agonist. As such, the risk of overdose is less with buprenorphine, particularly during the initiation phase (Kimber et al., Reference Kimber, Larney, Hickman, Randall and Degenhardt2015). However, sublingual buprenorphine formulations have been linked to concerns regarding diversion, misuse and other harms associated with intravenous drug use (Lofwall et al., Reference Lofwall and Walsh2014). Combinations of buprenorphine/naloxone have been developed to reduce this risk of abuse (Stoller et al., Reference Stoller, Bigelow, Walsh and Strain2001)

Methadone remains the first-line treatment of choice; however, there are certain circumstances whereby buprenorphine may be the preferred option. These include for patients with prolonged corrected QT-interval, patients treated for codeine dependence, patients who are in stable employment or education and patients diagnosed with HIV to facilitate alternative HIV treatment options (HSE, 2016). Recently, the numbers of people in receipt of buprenorphine as an OAT has increased due to a revised induction protocol developed during the COVID-19 pandemic, when the goal was to induct as many Opioid dependent people as possible onto treatment safely and quickly (HSE, 2020).

Oral methadone requires daily dosing while sublingual buprenorphine requires daily or alternate daily dosing. In the initial stages of treatment (i.e., induction and stabilisation), frequent supervised consumption is recommended (HSE, 2016).

Certain limitations and burdens that may be associated with conventional OAT include variable adherence, difficulty achieving optimal dosing, risks related to misuse, diversion and accidental exposure as well as stigma from the treatment process (Gilman et al., Reference Gilman, Li, Hudson, Lumley, Myers, Corte and Littlewood2018). The option of providing OAT using longer acting or slow release preparations has emerged as a viable alternative, and a number of services internationally are utilising this approach including in Australia and the UK (Larance et al., Reference Larance, Degenhardt and Grebely2019; Parsons et al., Reference Parsons, Ragbir, D’Agnone, Gibbs, Littlewood and Hard2020).

There are currently three different formulations of prolonged-release buprenorphine (PRB) worldwide – one subcutaneous implant (Sixmo) and two subcutaneous depot formulations (Sublocade and Buvidal) (Chappuy et al., Reference Chappuy, Trojak, Nubukpo, Bachellier, Bendimerad, Brousse and Rolland2020).

Sixmo is a six-month buprenorphine implant that is surgically inserted into the inner part of the upper arm. Treatment is limited to two successive implants, that is, 12 months in total, after which point, the patient is switched back to the oral form. It has been shown to be at least as effective as sublingual buprenorphine and is stored at room temperature.

Sublocade is a monthly subcutaneous buprenorphine depot that has been approved for use in the USA but not yet in the EU. There are two available monthly doses – 100 or 300 mg. It must be stored in a refrigerator (at between +2 and +8 °C) as its stability does not exceed seven days at room temperature.

Buvidal is the first PRB depot formulation that has received a European licence. It is available in weekly (8, 16, 24 or 32 mg) or monthly (64, 96 or 128 mg) doses and is stored at room temperature. The European Medicines Agency has concluded that Buvidal is at least as effective as sublingual buprenorphine at treating opioid dependence and offers an additional treatment option (EMA, 2018).

For patients, potential benefits of PRB formulations include reduced stigma, improved quality of life and more time available to complete other activities of living (Gilman et al., Reference Gilman, Li, Hudson, Lumley, Myers, Corte and Littlewood2018; Neale et al., Reference Neale, Tompkins, McDonald and Strang2018; Tompkins et al., Reference Tompkins, Neale and Strang2019). Participants from both an Australian and a UK sample reported perceived benefits of preventing opioid cravings and suppressing withdrawal symptoms for prolonged periods (Larance et al., Reference Larance, Degenhardt and Grebely2019, Tompkins et al., Reference Tompkins, Neale and Strang2019).

Of those who have had experience with Buvidal in the UK, there have been positive reports across areas of treatment effectiveness, convenience and overall satisfaction. The majority of the group reported specific benefits of reduced cravings, improvements in self-care and relationships and a more positive outlook on life (Parsons et al., Reference Parsons, Ragbir, D’Agnone, Gibbs, Littlewood and Hard2020).

A recent Australian open-label randomized control trial showed that patient-reported outcomes, such as treatment satisfaction with medication were significantly higher among patients treated with depot formulations of buprenorphine compared with sublingual buprenorphine (Lintzeris et al., Reference Lintzeris, Dunlop, Haber, Lubman, Graham, Hutchinson, Arunogiri, Hayes, Hjelmstrom, Svedberg, Peterson and Tiberg2021).

Buvidal is the first and currently the only PRB formulation that is available for use in Ireland. Treatment has been commenced on a pilot basis with a cohort of opioid dependent patients who are attending the HSE National Drug Treatment Centre and certain addiction services within the Dublin North County and City area. Initial reports seem positive. Longitudinal results and findings from this study are eagerly awaited to determine whether this is a viable option to expand treatment options in Ireland.

The Covid-19 pandemic presented specific challenges for addiction services in Ireland (Hennigan et al., Reference Hennigan, Corrigan, Killeen, Keenan and Scully2021). The availability of a prolonged release medication for OAT would have been of benefit in reducing attendances at addiction clinics and general practitioner surgeries and enhancing compliance with public health guidance on travel. This, in turn, would have resulted in additional safety measures and improved health outcomes for this vulnerable population.